Stemline Therapeutics Reports Fourth Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Stemline Therapeutics Reports Fourth Quarter 2015 Financial Results
March 16, 2016 9:20 AM EDT
Jefferies maintained a Buy rating on Stemline Therapeutics (NASDAQ: STML), and cut the price target to $23.00 (from $30.00), following the company's 4Q. STML continues to evaluate SL-401. STML reported a 86% ORR in the potentially pivotal BPDCN trial last December at ASH. Management... More
March 15, 2016 7:51 AM EDT
Wedbush maintained an Outperform rating on Stemline Therapeutics (NASDAQ: STML), and cut the price target to $15.00 (from $19.00), following the company's 4Q earnings report. STML reported a net loss of ($0.58) per share, in line with consensus' estimate of ($0.57). Management is expecting multiple clinical updates in 2016.... More
March 14, 2016 7:33 AM EDT
Stemline Therapeutics (NASDAQ: STML) reported Q4 EPS of ($0.58), $0.01 worse than the analyst estimate of ($0.57).
Stemline ended the fourth quarter of 2015 with $97.5 million in cash, cash equivalents and investments, as compared to $104.0 million as of September 30, 2015, which reflects a cash burn of $6.5... More
